insights_auto
Why is 4547 down 3,39%?
Dive Deeperchevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
3 700,00 JP¥
arrow_downward
-3,39%(-130,00) 1D
2 қаз., 15:30:00 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
3 810 JP¥
High
3 815 JP¥
Low
3 690 JP¥
Mkt. cap
172,21 млрд
Avg. vol.
66,55 мың
Volume
97,50 мың
Dividend
3,24%
Quarterly dividend
30 JP¥
Ex-dividend date
2026 ж. 29 қыр.
P/E ratio
10,97
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 млн
No. of employees
2 мың
Open
3 810 JP¥
High
3 815 JP¥
Low
3 690 JP¥
Mkt. cap
172,21 млрд
Avg. vol.
66,55 мың
Volume
97,50 мың
Dividend
3,24%
Quarterly dividend
30 JP¥
Ex-dividend date
2026 ж. 29 қыр.
P/E ratio
10,97
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 млн
No. of employees
2 мың
News stories
From web sources and news partners
PR Newswire
·
9 минут бұрын
Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
Business Insider
·
1 сағат бұрын
The NYSE's Most Famous Floor Trader Says AI Can't Take His Job
MarketBeat
·
1 сағат бұрын
Roth Capital Upgrades Suja Life (NASDAQ:SUJA) to Strong-Buy
WSJ
·
14 сағат бұрын
Nasdaq Leads Stocks Higher as Hiring Softens
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1,79 мың
Founded1946 ж. 09 там.
HeadquartersMatsumoto, Nagano, Жапония
SectorPharmaceutical industry
Websitekissei.co.jp